The world of spinal care continues to be divided among the slow-growing giants like Johnson & Johnson (JNJ), Medtronic (MDT), and Stryker (SYK) and the much faster-growing up-and-comers like NuVasive (NUVA) and Globus Medical (GMED).
With Globus maintaining a focus on continuous product development and
new launches and the expansion of its sales effort, the growth prospects
continue to look good, particularly as some industry headwinds appear
to be abating.
Valuation for med-tech has gotten trickier as the
stocks have been quite strong over the last year or so. Globus isn't so
appealing from the viewpoint of intrinsic value (discounted cash flow),
but the stock doesn't seem overpriced from the perspective of sales and
EBITDA multiples.
Continue reading here:
Globus Medical Staying On A Growth Track
No comments:
Post a Comment